Risk of bone overstimulation in long-term PTH(1-34) therapy for hypoparathyroidism by Rebecca Fischler et al
EJE Volume 194, Issue 4, April 2026
Open access 👉 https://doi.org/10.1093/ejendo/lvag053
#endocrinology #hypoparathyroidism #PTH(1-34) #teriparatide
EJE Volume 194, Issue 4, April 2026
Open access 👉 https://doi.org/10.1093/ejendo/lvag053
#endocrinology #hypoparathyroidism #PTH(1-34) #teriparatide
October 4, 2026 at 6:30 AM
Risk of bone overstimulation in long-term PTH(1-34) therapy for hypoparathyroidism by Rebecca Fischler et al
EJE Volume 194, Issue 4, April 2026
Open access 👉 https://doi.org/10.1093/ejendo/lvag053
#endocrinology #hypoparathyroidism #PTH(1-34) #teriparatide
EJE Volume 194, Issue 4, April 2026
Open access 👉 https://doi.org/10.1093/ejendo/lvag053
#endocrinology #hypoparathyroidism #PTH(1-34) #teriparatide
RCT: Among adults with osteogenesis imperfecta, teriparatide plus zoledronic acid improved bone mineral density and certain patient-reported outcomes but did not decrease new or recurrent fractures compared with standard care.
ja.ma/49F752B
ja.ma/49F752B
May 18, 2026 at 2:00 PM
RCT: Among adults with osteogenesis imperfecta, teriparatide plus zoledronic acid improved bone mineral density and certain patient-reported outcomes but did not decrease new or recurrent fractures compared with standard care.
ja.ma/49F752B
ja.ma/49F752B
Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study - Osteoporosis International
Summary This case-control study investigated the impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in postmenopausal osteoporosis. Romosozumab demonstrated the most s...
link.springer.com
January 19, 2025 at 11:19 AM
Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Romosozumab use in adults with osteoporosis was associated with a 21% reduction in risk for osteoarthritis, particularly knee osteoarthritis, compared with teriparatide use. ms.spr.ly/63320s1cso
July 26, 2025 at 1:00 PM
Romosozumab use in adults with osteoporosis was associated with a 21% reduction in risk for osteoarthritis, particularly knee osteoarthritis, compared with teriparatide use. ms.spr.ly/63320s1cso
Any chance you might offer Teriparatide on Cost Plus?
March 1, 2025 at 4:21 PM
Any chance you might offer Teriparatide on Cost Plus?
📊 Research Summary: Sequential teriparatide plus zoledronic acid increased bone mineral density in adults with osteogenesis imperfecta but did not lower fracture risk compared with standard care. ja.ma/4ue8m9k
May 14, 2026 at 3:30 PM
📊 Research Summary: Sequential teriparatide plus zoledronic acid increased bone mineral density in adults with osteogenesis imperfecta but did not lower fracture risk compared with standard care. ja.ma/4ue8m9k
Explore how to effectively integrate teriparatide into treatment plans on Tuesday, June 17 at 1:00 PM ET during Using Teriparatide: Combination and Sequential Therapies Member Webinar. Receive best practices for both sequential and concomitant use of teriparatide with other agents: bit.ly/3ZlTIzn
June 6, 2025 at 6:22 PM
Explore how to effectively integrate teriparatide into treatment plans on Tuesday, June 17 at 1:00 PM ET during Using Teriparatide: Combination and Sequential Therapies Member Webinar. Receive best practices for both sequential and concomitant use of teriparatide with other agents: bit.ly/3ZlTIzn
Thank you again ! Is there a significant difference between abaloparatide and teriparatide?
June 4, 2026 at 8:53 PM
Thank you again ! Is there a significant difference between abaloparatide and teriparatide?
From #ENDO2026: Transitioning to antiresorptive therapy after treatment with #abaloparatide or teriparatide reduces the risk of hip fractures among patients with #osteoporosis.
https://www.endocrinologyadvisor.com/reports/antiresorptive-therapy-abaloparatide-teriparatide-hip-fracture/
https://www.endocrinologyadvisor.com/reports/antiresorptive-therapy-abaloparatide-teriparatide-hip-fracture/
Antiresorptive Therapy After Anabolic Treatment Lowers Hip Fracture Risk
Antiresorptive therapy following abaloparatide or teriparatide treatment may reduce the risk of hip fractures in patients with osteoporosis.
www.endocrinologyadvisor.com
June 15, 2026 at 3:33 PM
From #ENDO2026: Transitioning to antiresorptive therapy after treatment with #abaloparatide or teriparatide reduces the risk of hip fractures among patients with #osteoporosis.
https://www.endocrinologyadvisor.com/reports/antiresorptive-therapy-abaloparatide-teriparatide-hip-fracture/
https://www.endocrinologyadvisor.com/reports/antiresorptive-therapy-abaloparatide-teriparatide-hip-fracture/
Synergistic effects of platelet-rich plasma and teriparatide on osteoporotic fracture healing i - goo.gl/alerts/jajB9U #GoogleAlerts
Synergistic effects of platelet-rich plasma and teriparatide on osteoporotic fracture healing in OVX rats - Scientific Reports
To evaluate the combined efficacy of locally injected platelet-rich plasma (PRP) and systemically administered teriparatide (PTH) on fracture healing in osteoporotic rats. Thirty female Sprague-Dawley...
goo.gl
April 2, 2026 at 12:02 PM
Synergistic effects of platelet-rich plasma and teriparatide on osteoporotic fracture healing i - goo.gl/alerts/jajB9U #GoogleAlerts
Twice-Weekly Teriparatide Boosts Osteoporosis Treatment Success - BIOENGINEER.ORG - goo.gl/alerts/z1NGq4 #GoogleAlerts
Twice-Weekly Teriparatide Boosts Osteoporosis Treatment Success
Osteoporosis remains a global health concern, particularly prevalent among older adults. The condition is characterized by a decrease in bone density, leading to an increased risk of fractures. With
goo.gl
January 26, 2026 at 12:53 PM
Twice-Weekly Teriparatide Boosts Osteoporosis Treatment Success - BIOENGINEER.ORG - goo.gl/alerts/z1NGq4 #GoogleAlerts
🔵 World Osteoporosis Day 🔵
In support of #WorldOsteoporosisDay, we spotlighting some of our key Reviews
📘 Featured read: Parathyroid hormone receptor agonists in the management of osteoporosis
👉 bit.ly/47zJiR2
#Rheumsky #Medsky
In support of #WorldOsteoporosisDay, we spotlighting some of our key Reviews
📘 Featured read: Parathyroid hormone receptor agonists in the management of osteoporosis
👉 bit.ly/47zJiR2
#Rheumsky #Medsky
Parathyroid hormone receptor agonists in the management of osteoporosis - Nature Reviews Rheumatology
This Review summarizes clinical effectiveness, health economics and safety data on the parathyroid hormone receptor agonists teriparatide and abaloparatide, discussing potential strategies and drug co...
bit.ly
October 20, 2025 at 1:52 PM
🔵 World Osteoporosis Day 🔵
In support of #WorldOsteoporosisDay, we spotlighting some of our key Reviews
📘 Featured read: Parathyroid hormone receptor agonists in the management of osteoporosis
👉 bit.ly/47zJiR2
#Rheumsky #Medsky
In support of #WorldOsteoporosisDay, we spotlighting some of our key Reviews
📘 Featured read: Parathyroid hormone receptor agonists in the management of osteoporosis
👉 bit.ly/47zJiR2
#Rheumsky #Medsky
Romosozumab mitigates progression from radiological to symptomatic adjacent-level vertebral fractures after cement augmentation compared to teriparatide after two years. Wei‑Han Kao et al. Osteoporos Int 16 Dec 2025 shorturl.at/qjfK0
Romosozumab mitigates progression from radiological to symptomatic adjacent-level fractures compared to teriparatide - Osteoporosis International
Summary Romosozumab and teriparatide were compared for preventing symptomatic subsequent vertebral compression fractures (SVCF) after cement augmentation. Across multicenter and hospital-based cohorts...
shorturl.at
December 23, 2025 at 8:11 AM
Romosozumab mitigates progression from radiological to symptomatic adjacent-level vertebral fractures after cement augmentation compared to teriparatide after two years. Wei‑Han Kao et al. Osteoporos Int 16 Dec 2025 shorturl.at/qjfK0
Prolonged hypercalcemia induced by teriparatide: a case report and literature review. Jing Lin et al. Osteoporos Int 11 June 2025 doi.org/10.1007/s001... … personalized dosing strategies, particularly for underweight patients
June 13, 2025 at 8:44 AM
Prolonged hypercalcemia induced by teriparatide: a case report and literature review. Jing Lin et al. Osteoporos Int 11 June 2025 doi.org/10.1007/s001... … personalized dosing strategies, particularly for underweight patients
🦴 My newest paper out in Osteoporosis International!
Australian real-world data on romosozumab vs teriparatide vs antiresorptives. Lumbar spine BMD gains: 11.3% vs 5.0% vs 6.6%. Treatment-naïve patients benefit most.
doi.org/10.1007/s001...
#Osteoporosis #Endocrinology
Australian real-world data on romosozumab vs teriparatide vs antiresorptives. Lumbar spine BMD gains: 11.3% vs 5.0% vs 6.6%. Treatment-naïve patients benefit most.
doi.org/10.1007/s001...
#Osteoporosis #Endocrinology
March 25, 2026 at 2:53 PM
🦴 My newest paper out in Osteoporosis International!
Australian real-world data on romosozumab vs teriparatide vs antiresorptives. Lumbar spine BMD gains: 11.3% vs 5.0% vs 6.6%. Treatment-naïve patients benefit most.
doi.org/10.1007/s001...
#Osteoporosis #Endocrinology
Australian real-world data on romosozumab vs teriparatide vs antiresorptives. Lumbar spine BMD gains: 11.3% vs 5.0% vs 6.6%. Treatment-naïve patients benefit most.
doi.org/10.1007/s001...
#Osteoporosis #Endocrinology
Effectiveness of anti-osteoporotic medications in glucocorticoid-induced osteoporosis: syst.review and meta-analysis; ECTS Clinical Action Group. MP Yavropoulou et al. Eur J Endocrinol 2026 Aug 7 shorturl.at/eRjJN … greatest increase of LBMD by teriparatide and romosozumab
August 10, 2026 at 8:00 AM
Effectiveness of anti-osteoporotic medications in glucocorticoid-induced osteoporosis: syst.review and meta-analysis; ECTS Clinical Action Group. MP Yavropoulou et al. Eur J Endocrinol 2026 Aug 7 shorturl.at/eRjJN … greatest increase of LBMD by teriparatide and romosozumab
The February 2025 #EndocrinePractice is now available with articles on Cushing's Syndrome, the effectiveness of Abaloparatide and Teriparatide in women 50 years of age and older, and more. Read the issue today: www.endocrinepractice.org/current #endocrinology @vtangpricha.bsky.social
February 12, 2025 at 7:51 PM
The February 2025 #EndocrinePractice is now available with articles on Cushing's Syndrome, the effectiveness of Abaloparatide and Teriparatide in women 50 years of age and older, and more. Read the issue today: www.endocrinepractice.org/current #endocrinology @vtangpricha.bsky.social
Dr. Barbara Hauser has come to #ECTS2025 with Elizabeth Orhadje, who will be now presenting the poster "Real-world efficacy analysis of 12 months romosozumab followed by 12 month antiresorptive treatment compared to 24 months teriparatide". Come and see 👀!!
May 26, 2025 at 12:03 PM
Dr. Barbara Hauser has come to #ECTS2025 with Elizabeth Orhadje, who will be now presenting the poster "Real-world efficacy analysis of 12 months romosozumab followed by 12 month antiresorptive treatment compared to 24 months teriparatide". Come and see 👀!!
Our latest Shortcast features Mark Wijnen reporting the use of teriparatide to treat bone disease in 2 patients with in MPS Type IVB.
Listen on Spotify: open.spotify.com/episode/6z3Q...
or wherever you get your podcasts
#MPS #Podcast #raredisease
Listen on Spotify: open.spotify.com/episode/6z3Q...
or wherever you get your podcasts
#MPS #Podcast #raredisease
June 16, 2026 at 3:33 PM
Our latest Shortcast features Mark Wijnen reporting the use of teriparatide to treat bone disease in 2 patients with in MPS Type IVB.
Listen on Spotify: open.spotify.com/episode/6z3Q...
or wherever you get your podcasts
#MPS #Podcast #raredisease
Listen on Spotify: open.spotify.com/episode/6z3Q...
or wherever you get your podcasts
#MPS #Podcast #raredisease
In a few minutes, you'll have time to visit P211 by @b-hauser.bsky.social 🇩🇪 entitled "Mortality and Cardiovascular events in patients with severe Osteoporosis Treated with Romosozumab Followed by Antiresorptive Therapy: A Comparative Analysis with Teriparatide in a Single-Centre Study". #ECTS2025
May 25, 2025 at 2:02 PM
In a few minutes, you'll have time to visit P211 by @b-hauser.bsky.social 🇩🇪 entitled "Mortality and Cardiovascular events in patients with severe Osteoporosis Treated with Romosozumab Followed by Antiresorptive Therapy: A Comparative Analysis with Teriparatide in a Single-Centre Study". #ECTS2025
Romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis. Masaki Hatano et al. Ann Rheum Dis 2025 Jul 4 shorturl.at/LWz4v …new user comparative effectiveness Japanese study
Redirecting
shorturl.at
July 17, 2025 at 7:22 AM
Romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis. Masaki Hatano et al. Ann Rheum Dis 2025 Jul 4 shorturl.at/LWz4v …new user comparative effectiveness Japanese study
The effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis - The Lancet Healthy Longevity www.thelancet.com/journals/lan...
The effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis
On the basis of these analyses, bisphosphonate therapy did not appear to affect the
time to or rate of fracture healing. Teriparatide does not appear to delay healing
and might reduce the time to unio...
www.thelancet.com
June 9, 2026 at 1:54 PM
The effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis - The Lancet Healthy Longevity www.thelancet.com/journals/lan...
Effects of romosozumab and teriparatide on hip bone using 3D-SHAPER in PMP women with osteoporosis. EM Lewiecki et al. JBMR Plus 11Oct 2025 shorturl.at/kxUf3 …growing evidence that romosozumab improves hip cortical bone density and structure, contributing to its antifracture efficacy
October 19, 2025 at 8:19 AM
Effects of romosozumab and teriparatide on hip bone using 3D-SHAPER in PMP women with osteoporosis. EM Lewiecki et al. JBMR Plus 11Oct 2025 shorturl.at/kxUf3 …growing evidence that romosozumab improves hip cortical bone density and structure, contributing to its antifracture efficacy
